Ciltacabtagene Autoleucel Shows Benefits for Patients With High-Risk Smoldering Multiple Myeloma

Patients with high-risk smoldering multiple myeloma who were treated with a single infusion of ciltacabtagene autoleucel (Carvykti) remained negative for minimal residual disease (MRD) after two months, according to results of the PRecision Intervention Smoldering Myeloma (CAR-PRISM) trial. The results were presented at the American Association for Cancer Research Annual Meeting, held earlier this month in San Diego, and were also published in Nature Medicine.

The CAR-PRISM trial, a single-center, phase 2 trial, examined the effects of a CAR T-cell therapy in 20 patients with high-risk smoldering multiple myeloma. The results demonstrated that all 20 patients were negative for MRD not only at the end of the two-month follow-up period, but remained so after a medium of 15.3 months of follow-up. In addition, no patients reported experiencing high-grade side effects.

“Within two months, all patients were MRD-negative at the deepest level we can measure, and at 15 months or so of follow up, everyone remains MRD-negative,” said Omar Nadeem, MD, clinical director of the myeloma immune effector cell therapy program at Dana-Farber Cancer Institute, who presented the results. “This is the first time this kind of result has been reported in any spectrum of myeloma and really shows the efficacy of CAR T-cells in earlier disease state.”